

Huib A M Kerstjens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1295577/publications.pdf>

Version: 2024-02-01

287
papers

14,679
citations

26630

56
h-index

22166

113
g-index

295
all docs

295
docs citations

295
times ranked

12282
citing authors

#	ARTICLE	IF	CITATIONS
1	Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings. <i>Respiration</i> , 2022, 101, 184-189.	2.6	9
2	Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Virus Infections in Lung Transplant Recipients: A Systematic Review of Outcomes and Treatment Strategies. <i>Clinical Infectious Diseases</i> , 2022, 74, 2252-2260.	5.8	14
3	Clinical Relevance of Rifampicin-Moxifloxacin Interaction in Isoniazid-Resistant/Intolerant Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0182921.	3.2	4
4	Bronchial wall parameters on CT in healthy never-smoking, smoking, COPD, and asthma populations: a systematic review and meta-analysis. <i>European Radiology</i> , 2022, 32, 5308-5318.	4.5	5
5	Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone. <i>International Journal of COPD</i> , 2022, Volume 17, 355-370.	2.3	5
6	Reduction of Lung Hyperinflation Improves Cardiac Preload, Contractility, and Output in Emphysema: A Clinical Trial in Patients Who Received Endobronchial Valves. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 704-711.	5.6	17
7	A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study. <i>ERJ Open Research</i> , 2022, 8, 00129-2022.	2.6	9
8	Function-specific IL-17A and dexamethasone interactions in primary human airway epithelial cells. <i>Scientific Reports</i> , 2022, 12, .	3.3	8
9	Prostaglandin D2: the end of a story or just the beginning?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 2-3.	10.7	7
10	Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 69-84.	10.7	135
11	Inhaled long-acting muscarinic antagonists in asthma – A narrative review. <i>European Journal of Internal Medicine</i> , 2021, 85, 14-22.	2.2	18
12	Provision of Palliative Care in Patients with COPD: A Survey Among Pulmonologists and General Practitioners. <i>International Journal of COPD</i> , 2021, Volume 16, 783-794.	2.3	7
13	Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials. <i>Respiratory Medicine</i> , 2021, 180, 106311.	2.9	8
14	Determinants of Lung Fissure Completeness. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 807-816.	5.6	6
15	The sputum transcriptome better predicts COPD exacerbations after the withdrawal of inhaled corticosteroids than sputum eosinophils. <i>ERJ Open Research</i> , 2021, 7, 00097-2021.	2.6	7
16	High Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 851-861.	3.4	9
17	Stability in eosinophil categorisation during subsequent severe exacerbations of COPD. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000960.	3.0	5
18	Imaging the pulmonary extracellular matrix. <i>Current Opinion in Physiology</i> , 2021, 22, 100444.	1.8	0

#	ARTICLE	IF	CITATIONS
19	Chronic non-invasive ventilation for chronic obstructive pulmonary disease. The Cochrane Library, 2021, 2021, CD002878.	2.8	21
20	One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies. BMJ Open Respiratory Research, 2021, 8, e000819.	3.0	4
21	Opioids in patients with COPD and refractory dyspnea: literature review and design of a multicenter double blind study of low dosed morphine and fentanyl (MoreFoRCOPD). BMC Pulmonary Medicine, 2021, 21, 289.	2.0	5
22	Responsivity and Reproducibility of Sputum Inflammatory Biomarkers During COPD Exacerbation and Stable Phases – A Pilot Study. International Journal of COPD, 2021, Volume 16, 3055-3064.	2.3	1
23	Predicting Mortality in COPD with Validated and Sensitive Biomarkers; Fibrinogen and Mid-Range-Proadrenomedullin (MR-proADM). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 643-649.	1.6	2
24	Malnutrition assessment methods in adult patients with tuberculosis: a systematic review. BMJ Open, 2021, 11, e049777.	1.9	4
25	Respiratory Syncytial Virus Infection Morbidity in the Elderly: Time for Repurposing of Ribavirin?. Clinical Infectious Diseases, 2020, 70, 2238-2239.	5.8	4
26	Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2–5. Pulmonary Pharmacology and Therapeutics, 2020, 60, 101881.	2.6	8
27	Treatment of severe stable COPD: the multidimensional approach of treatable traits. ERJ Open Research, 2020, 6, 00322-2019.	2.6	21
28	Time to rename COPD exacerbations: implementing the term lung attack. Lancet Respiratory Medicine, the, 2020, 8, e25.	10.7	5
29	<p>Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study</p>. International Journal of COPD, 2020, Volume 15, 2739-2750.	2.3	0
30	Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respiratory Medicine, the, 2020, 8, 1000-1012.	10.7	98
31	<p>An Integrative Approach of the Fissure Completeness Score and Chartis Assessment in Endobronchial Valve Treatment for Emphysema</p>. International Journal of COPD, 2020, Volume 15, 1325-1334.	2.3	28
32	<p>Reducing the Number of Hospitalization Days for COPD: Setting up a Transmural-Care Pathway</p>. International Journal of COPD, 2020, Volume 15, 2367-2377.	2.3	8
33	A cluster randomized controlled trial on a multifaceted implementation strategy to promote integrated palliative care in COPD: study protocol of the COMPASSION study. BMC Palliative Care, 2020, 19, 155.	1.8	5
34	Identifying a nasal gene expression signature associated with hyperinflation and treatment response in severe COPD. Scientific Reports, 2020, 10, 17415.	3.3	2
35	Asthma exacerbations and worsenings in patients aged 1–75 years with add-on tiotropium treatment. Npj Primary Care Respiratory Medicine, 2020, 30, 38.	2.6	5
36	Caring for patients with COPD and COVID-19: a viewpoint to spark discussion. Thorax, 2020, 75, 1035-1039.	5.6	15

#	ARTICLE	IF	CITATIONS
37	The effects of lung volume reduction treatment on diffusing capacity and gas exchange. <i>European Respiratory Review</i> , 2020, 29, 190171.	7.1	5
38	Tiotropium Respimat Efficacy and Safety in Asthma: Relationship to Age. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2653-2660.e4.	3.8	9
39	Temporary Right Middle Lobe Occlusion with a Blocking Device to Enable Collateral Ventilation Measurement of the Right Major Fissure. <i>Respiration</i> , 2020, 99, 516-520.	2.6	2
40	Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis. <i>Pulmonary Therapy</i> , 2020, 6, 131-140.	2.2	2
41	Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial. <i>Respiratory Medicine</i> , 2020, 171, 106064.	2.9	3
42	Sputum microbiome profiling in COPD: beyond singular pathogen detection. <i>Thorax</i> , 2020, 75, 338-344.	5.6	37
43	Endobronchial Valve Treatment in Emphysema Patients with a Very Low DLCO. <i>Respiration</i> , 2020, 99, 163-170.	2.6	16
44	Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial. <i>Thorax</i> , 2020, 75, 244-252.	5.6	121
45	Evaluation of 10 years of parainfluenza virus, human metapneumovirus, and respiratory syncytial virus infections in lung transplant recipients. <i>American Journal of Transplantation</i> , 2020, 20, 3529-3537.	4.7	19
46	<p>Patient Selection for Bronchoscopic Lung Volume Reduction</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 871-881.	2.3	13
47	Predicted values for the forced expiratory flow adjusted for forced vital capacity, a descriptive study. <i>ERJ Open Research</i> , 2020, 6, 00426-2020.	2.6	2
48	Safety of tiotropium Respimat® in black or African-American patients with symptomatic asthma. <i>Respiratory Medicine</i> , 2019, 155, 58-60.	2.9	5
49	Repurposed Oral Ribavirin for Respiratory Virus Infections Requires Pharmacokinetic-pharmacodynamic Dose Optimization. <i>Clinical Infectious Diseases</i> , 2019, 70, 1258.	5.8	1
50	Blood eosinophils as a continuous variable in the treatment of COPD: impact on the guidelines. <i>Lancet Respiratory Medicine</i> , 2019, 7, 722-723.	10.7	9
51	Collateral Ventilation Measurement Using Chartis. <i>Chest</i> , 2019, 156, 984-990.	0.8	12
52	Airway pharmacology: treatment options and algorithms to treat patients with chronic obstructive pulmonary disease. <i>Journal of Thoracic Disease</i> , 2019, 11, S2200-S2209.	1.4	9
53	Tiotropium Respimat® add-on therapy to inhaled corticosteroids in patients with symptomatic asthma improves clinical outcomes regardless of baseline characteristics. <i>Respiratory Medicine</i> , 2019, 158, 97-109.	2.9	17
54	A New Oxygen Uptake Measurement Supporting Target Selection for Endobronchial Valve Treatment. <i>Respiration</i> , 2019, 98, 521-526.	2.6	3

#	ARTICLE	IF	CITATIONS
55	Significant Differences in Body Plethysmography Measurements Between Hospitals in Patients Referred for Bronchoscopic Lung Volume Reduction. <i>Lung</i> , 2019, 197, 573-576.	3.3	1
56	A review on the pathophysiology of asthma remission. , 2019, 201, 8-24.		36
57	Associations of AMP and adenosine induced dyspnea sensation to large and small airways dysfunction in asthma. <i>BMC Pulmonary Medicine</i> , 2019, 19, 23.	2.0	5
58	Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests. <i>European Respiratory Journal</i> , 2019, 53, 1801660.	6.7	102
59	Clinical- and Cost-Effectiveness of a Mandibular Advancement Device Versus Continuous Positive Airway Pressure in Moderate Obstructive Sleep Apnea. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1477-1485.	2.6	24
60	Assessing small airways dysfunction in asthma, asthma remission and healthy controls using particles in exhaled air. <i>ERJ Open Research</i> , 2019, 5, 00202-2019.	2.6	2
61	Gene network approach reveals co-expression patterns in nasal and bronchial epithelium. <i>Scientific Reports</i> , 2019, 9, 15835.	3.3	14
62	Factors associated with hyperresponsiveness to adenosine 5'-monophosphate in healthy subjects. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2268-2270.	5.7	1
63	Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300mg linezolid dosages using in-house made capsules. <i>European Respiratory Journal</i> , 2019, 54, 1900580.	6.7	21
64	Long-Term Objective Adherence to Mandibular Advancement Device Therapy Versus Continuous Positive Airway Pressure in Patients With Moderate Obstructive Sleep Apnea. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1655-1663.	2.6	20
65	Predictive value of eosinophils and neutrophils on clinical effects of ICS in COPD. <i>Respirology</i> , 2018, 23, 1023-1031.	2.3	24
66	Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2018, 51, 1702490.	6.7	7
67	Nasal epithelium as a proxy for bronchial epithelium for smoking-induced gene expression and expression Quantitative Trait Loci. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 314-317.e15.	2.9	32
68	Efficacy of tiotropium in adults with moderate asthma, by leukotriene receptor antagonist use at baseline. <i>Allergy International</i> , 2018, 67, 411-413.	3.3	2
69	Cardiovascular effects of oral appliance therapy in obstructive sleep apnea: A systematic review and meta-analysis. <i>Sleep Medicine Reviews</i> , 2018, 40, 55-68.	8.5	45
70	Minimal important difference of target lobar volume reduction after endobronchial valve treatment for emphysema. <i>Respirology</i> , 2018, 23, 306-310.	2.3	30
71	Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 923-935.e9.	3.8	64
72	Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018, Volume 13, 1269-1277.	2.3	10

#	ARTICLE	IF	CITATIONS
73	Changes in ventilation–perfusion during and after an COPD exacerbation: an assessment using fluid dynamic modeling. International Journal of COPD, 2018, Volume 13, 833-842.	2.3	8
74	Ageing-related trajectories of lung function in the general population"The Doetinchem Cohort Study. PLoS ONE, 2018, 13, e0197250.	2.5	24
75	Chartis Measurement of Collateral Ventilation: Conscious Sedation versus General Anesthesia " A Retrospective Comparison. Respiration, 2018, 96, 480-487.	2.6	12
76	Functional respiratory imaging: heterogeneity of acute exacerbations of COPD. International Journal of COPD, 2018, Volume 13, 1783-1792.	2.3	8
77	Variability and cost implications of three generations of the Roche LightCycler® 480. PLoS ONE, 2018, 13, e0190847.	2.5	5
78	Giants in Chest Medicine: Dirkje S. Postma, MD, PhD. Chest, 2018, 153, 1296-1298.	0.8	1
79	Pharmacokinetics of tiotropium administered by Respimat® in asthma patients: Analysis of pooled data from Phase II and III clinical trials. Pulmonary Pharmacology and Therapeutics, 2017, 42, 25-32.	2.6	12
80	Emerging bronchoscopic treatments for chronic obstructive pulmonary disease. , 2017, 179, 96-101.		23
81	Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1601724.	6.7	20
82	Neurological and functional recovery in"tuberculosis patients with spinal cord"injury in The Netherlands. NeuroRehabilitation, 2017, 40, 439-445.	1.3	8
83	Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. European Respiratory Journal, 2017, 49, 1600839.	6.7	22
84	Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2017, 377, 1613-1629.	27.0	397
85	Extrafine compared to non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma. Respiratory Medicine, 2017, 130, 35-42.	2.9	9
86	Assessment of Burden of COPD tool: evidence not perception. European Respiratory Journal, 2017, 50, 1700756.	6.7	0
87	Pleural Adhesion Assessment as a Predictor for Pneumothorax after Endobronchial Valve Treatment. Respiration, 2017, 94, 224-231.	2.6	25
88	Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. European Respiratory Journal, 2017, 49, 1700848.	6.7	13
89	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. Journal of Nutrition, Health and Aging, 2017, 21, 92-104.	3.3	47
90	Increased neutrophil expression of pattern recognition receptors during <sc>COPD</sc> exacerbations. Respirology, 2017, 22, 401-404.	2.3	24

#	ARTICLE	IF	CITATIONS
91	Stable State Proadrenomedullin Level in COPD Patients: A Validation Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 219-227.	1.6	5
92	Nasal gene expression differentiates COPD from controls and overlaps bronchial gene expression. Respiratory Research, 2017, 18, 213.	3.6	33
93	Real-life data on antibiotic prescription and sputum culture diagnostics in acute exacerbations of COPD in primary care. International Journal of COPD, 2017, Volume 12, 285-290.	2.3	18
94	Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD. , 2017, , .		1
95	Efficacy of once-daily tiotropium Respimat in adults with asthma based on GINA Steps 2â€“5. , 2017, , .		2
96	A nasal gene expression profile differentiates individuals with and without COPD and overlaps bronchial gene expression. , 2017, , .		0
97	Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics. , 2017, , .		0
98	Extrafine compared to non-extrafine particle ICS in smokers and ex-smokers with asthma. , 2017, , .		0
99	Minimal important difference of lobar volume reduction after valve treatment for emphysema. , 2017, , .		0
100	Comparison of gene expression profiles from nasal and bronchial brushes. , 2017, , .		0
101	Systematic review on shared decision making for patients with lung cancer: Effects on distress and health care utilization.. Journal of Clinical Oncology, 2017, 35, 31-31.	1.6	4
102	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients. PLoS ONE, 2016, 11, e0149768.	2.5	25
103	Safety and tolerability of once-daily tiotropium Respimat Â® as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. Respiratory Medicine, 2016, 118, 102-111.	2.9	31
104	Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. European Respiratory Journal, 2016, 48, 1800-1802.	6.7	9
105	Effectiveness of the Assessment of Burden of COPD (ABC) tool on health-related quality of life in patients with COPD: a cluster randomised controlled trial in primary and hospital care. BMJ Open, 2016, 6, e011519.	1.9	35
106	Tiotropium RespimatÂ® Add-on to at Least Ics Therapy Demonstrates Reduced Risk of Severe Asthma Exacerbation and Asthma Worsening in Symptomatic Asthma, Independent of IgE or Blood Eosinophil Levels. Journal of Allergy and Clinical Immunology, 2016, 137, AB214.	2.9	3
107	Once-Daily Tiotropium RespimatÂ® Add-on to at Least Ics Maintenance Therapy Demonstrates Improved Lung Function in Patients with Symptomatic Asthma, Independent of Serum IgE or Blood Eosinophil Levels. Journal of Allergy and Clinical Immunology, 2016, 137, AB213.	2.9	3
108	Once-Daily Tiotropium RespimatÂ® Add-on to at Least Ics Maintenance Therapy in Patients with Symptomatic Asthma: Methodology of Modeling Analyses By Serum IgE and Blood Eosinophil Levels. Journal of Allergy and Clinical Immunology, 2016, 137, AB212.	2.9	2

#	ARTICLE	IF	CITATIONS
109	Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD. The Cochrane Library, 2016, 2016, CD011826.	2.8	30
110	Fighting chronic lung diseases on a national level: The Dutch national action programme. International Journal of Care Coordination, 2016, 19, 65-72.	0.4	4
111	Tiotropium for the treatment of asthma: a drug safety evaluation. Expert Opinion on Drug Safety, 2016, 15, 1115-1124.	2.4	11
112	Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by an electronic nose: a pilot study. Journal of Breath Research, 2016, 10, 036001.	3.0	57
113	Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respiratory Medicine, 2016, 117, 198-206.	2.9	87
114	(Cost-effectiveness of self-treatment of exacerbations in patients with COPD: 2 years follow-up of a RCT). Respirology, 2016, 21, 497-503.	2.3	15
115	The Assessment of Burden of COPD (ABC) Scale: A Reliable and Valid Questionnaire. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 431-438.	1.6	19
116	Cost-Effectiveness of a Community-Based Exercise Programme in COPD Self-Management. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 214-223.	1.6	13
117	The assessment of burden of COPD (ABC) tool: What counts most?. , 2016, , .		0
118	Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients. , 2016, , .		0
119	Diagnosing viral and bacterial respiratory infections in acute COPD exacerbations by electronic nose. , 2016, , .		0
120	Is home mechanical ventilation really effective in patients with amyotrophic lateral sclerosis?. , 2016, , .		0
121	Bronchodilators delivered by nebuliser versus pMDI for exacerbations of COPD - A Cochrane review. , 2016, , .		0
122	The assessment of burden of COPD tool improves health related quality of life. , 2016, , .		0
123	Effects of ICS/LABA treatment on hyperinflation and genome wide gene-expression in upper airway epithelium in severe COPD. , 2016, , .		0
124	Relapse in FEV1 Decline After Steroid Withdrawal in COPD. Chest, 2015, 148, 389-396.	0.8	33
125	Once-Daily Tiotropium Respimat Add-on to Medium-Dose Inhaled Corticosteroids Improves Lung Function and Asthma Control in Adult Patients With Moderate Symptomatic Asthma, Independent of Prior Long-Acting β_2 -Agonist Use. Chest, 2015, 148, 732A.	0.8	1
126	Once-Daily Tiotropium Respimat Reduces Risk of Severe Asthma Exacerbation and Asthma Worsening in Symptomatic Asthma, Independent of Allergic and Inflammatory Status. Chest, 2015, 148, 671A.	0.8	2

#	ARTICLE	IF	CITATIONS
127	Hyperinflation in COPD exacerbations. <i>Lancet Respiratory Medicine</i> ,the, 2015, 3, e43-e44.	10.7	16
128	Usage of Positional Therapy in Adults with Obstructive Sleep Apnea. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 131-137.	2.6	61
129	Adrenomedullin optimises mortality prediction in COPD patients. <i>Respiratory Medicine</i> , 2015, 109, 734-742.	2.9	20
130	Tiotropium attenuates IL-13-induced goblet cell metaplasia of human airway epithelial cells. <i>Thorax</i> , 2015, 70, 668-676.	5.6	46
131	Determining the Role of Dynamic Hyperinflation in Patients with Severe Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2015, 90, 306-313.	2.6	21
132	Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. <i>New England Journal of Medicine</i> , 2015, 373, 2325-2335.	27.0	376
133	Anti-inflammatory effects of targeted lung denervation in patients with COPD. <i>European Respiratory Journal</i> , 2015, 46, 1489-1492.	6.7	33
134	Short- and long-term effects of a physical activity counselling programme in COPD: A randomized controlled trial. <i>Respiratory Medicine</i> , 2015, 109, 112-121.	2.9	99
135	Once-daily Tiotropium Respimat® Add-on to at Least ICS Maintenance Therapy Reduces Airflow Obstruction in Patients with Symptomatic Asthma, Independent of Allergic Status. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, AB6.	2.9	1
136	Regular treatment for moderate asthma: guidelines hold true. <i>Lancet Respiratory Medicine</i> ,the, 2015, 3, 88-89.	10.7	6
137	Muscarinic M ₃ receptors on structural cells regulate cigarette smoke-induced neutrophilic airway inflammation in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2015, 308, L96-L103.	2.9	25
138	Indacaterol vs tiotropium in COPD patients classified as GOLD A and B. <i>Respiratory Medicine</i> , 2015, 109, 1031-1039.	2.9	10
139	Tiotropium in asthma – Authors' reply. <i>Lancet Respiratory Medicine</i> ,the, 2015, 3, e17.	10.7	0
140	Bronchodilator reversibility and cardiac considerations with use of tiotropium. <i>Lancet Respiratory Medicine</i> ,the, 2015, 3, e25-e26.	10.7	2
141	The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 101-108.	2.6	8
142	Changes in the endurance shuttle walk test in COPD patients with chronic respiratory failure after pulmonary rehabilitation: the minimal important difference obtained with anchor- and distribution-based method. <i>Respiratory Research</i> , 2015, 16, 27.	3.6	26
143	Increased serum levels of LL37, HMGB1 and S100A9 during exacerbation in COPD patients. <i>European Respiratory Journal</i> , 2015, 45, 1482-1485.	6.7	49
144	Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. <i>Lancet Respiratory Medicine</i> ,the, 2015, 3, 367-376.	10.7	153

#	ARTICLE	IF	CITATIONS
145	Telemedicine, the effect of nurse-initiated telephone follow up, on health status and health care utilization in COPD patients: A randomized trial. <i>Respirology</i> , 2015, 20, 279-285.	2.3	31
146	Selecting the increment size for a maximal incremental cycle test in patients with COPD. <i>Respirology</i> , 2015, 20, 352-355.	2.3	5
147	Revisiting the Dutch hypothesis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 521-529.	2.9	62
148	Validity and Predictive Value of a Portable Two-Channel Sleep-Screening Tool in the Identification of Sleep Apnea in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 848-855.	1.7	17
149	Tiotropium add-on therapy in patients with uncontrolled asthma. <i>International Journal of Tuberculosis and Lung Disease</i> , 2015, 19, 1553-1553.	1.2	2
150	Changes in FEV1 after recovery from COPD exacerbation are driven by heterogeneous regional changes in airway caliber and hyperinflation. , 2015, , .		1
151	Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0143793.	2.5	18
152	Current role of anticholinergic drugs in the treatment of asthma: key messages for clinical practice. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 859-866.	0.4	1
153	Health status in patients with coexistent COPD and heart failure: a validation and comparison between the Clinical COPD Questionnaire and the Minnesota Living with Heart Failure Questionnaire. <i>International Journal of COPD</i> , 2014, 9, 999.	2.3	6
154	Muscarinic M ₃ Receptors Contribute to Allergen-Induced Airway Remodeling in Mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 50, 690-698.	2.9	58
155	Necessity of amoxicillin clavulanic acid in addition to prednisolone in mild-to-moderate COPD exacerbations. <i>BMJ Open Respiratory Research</i> , 2014, 1, e000052.	3.0	13
156	Hemoptysis and Hydrocephalus. Follow the Lead. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, e6-e6.	5.6	0
157	Lung Volume Reduction Coil Treatment in Chronic Obstructive Pulmonary Disease Patients with Homogeneous Emphysema: A Prospective Feasibility Trial. <i>Respiration</i> , 2014, 88, 116-125.	2.6	74
158	A community-based exercise programme in COPD self-management: Two years follow-up of the COPE-II study. <i>Respiratory Medicine</i> , 2014, 108, 1481-1490.	2.9	21
159	Effectiveness of the Assessment of Burden of Chronic Obstructive Pulmonary Disease (ABC) tool: study protocol of a cluster randomised trial in primary and secondary care. <i>BMC Pulmonary Medicine</i> , 2014, 14, 131.	2.0	13
160	Tiotropium Respimat® Add-On Therapy Reduces Airflow Obstruction In Patients With Symptomatic Moderate Asthma, Independent Of TH2 Inflammatory Status. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB5.	2.9	5
161	Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. <i>Thorax</i> , 2014, 69, 826-834.	5.6	246
162	The effect of an outpatient care on-demand-system on health status and costs in patients with COPD. A randomized trial. <i>Respiratory Medicine</i> , 2014, 108, 1163-1170.	2.9	10

#	ARTICLE	IF	CITATIONS
163	Development of the Assessment of Burden of COPD tool: an integrated tool to measure the burden of COPD. <i>Npj Primary Care Respiratory Medicine</i> , 2014, 24, 14021.	2.6	27
164	Stable-State Midrange-Proadrenomedullin Level Is a Strong Predictor of Mortality in Patients With COPD. <i>Chest</i> , 2014, 145, 534-541.	0.8	17
165	Usefulness of Midrange-Proadrenomedullin as a Predictor of Mortality in Patients With COPD: Response. <i>Chest</i> , 2014, 146, e65-e66.	0.8	1
166	Putting health status guided COPD management to the test: protocol of the MARCH study. <i>BMC Pulmonary Medicine</i> , 2013, 13, 41.	2.0	10
167	Functional and psychological variables both affect daily physical activity in COPD: A structural equations model. <i>Respiratory Medicine</i> , 2013, 107, 1740-1747.	2.9	41
168	Comparison of 14 Molecular Assays for Detection of Mycobacterium tuberculosis Complex in Bronchoalveolar Lavage Fluid. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3505-3511.	3.9	19
169	The Severe Respiratory Insufficiency Questionnaire scored best in the assessment of health-related quality of life in chronic obstructive pulmonary disease. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 1166-1174.	5.0	38
170	Pharmacological inhibition of GSK-3 in a guinea pig model of LPS-induced pulmonary inflammation: I. Effects on lung remodeling and pathology. <i>Respiratory Research</i> , 2013, 14, 113.	3.6	17
171	Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics. <i>BMC Pulmonary Medicine</i> , 2013, 13, 58.	2.0	36
172	Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. <i>Respiratory Research</i> , 2013, 14, 125.	3.6	49
173	Efficacy of Tiotropium in Patients with Asthma in Relation to Allergic Status. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, AB1.	2.9	2
174	Muscarinic receptor subtype-specific effects on cigarette smoke-induced inflammation in mice. <i>European Respiratory Journal</i> , 2013, 42, 1677-1688.	6.7	44
175	Glycogen synthase kinase-3 (GSK-3) regulates $\text{TGF}\beta^2$ -induced differentiation of pulmonary fibroblasts. <i>British Journal of Pharmacology</i> , 2013, 169, 590-603.	5.4	51
176	Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2013, , CD002878.	2.8	73
177	Once-Daily Tiotropium Reduces Risk of Exacerbations and Asthma Worsening in Patients With Symptomatic Asthma Despite Treatment With Inhaled Corticosteroids and Long-Acting β_2 -Agonists. <i>Chest</i> , 2013, 144, 90A.	0.8	2
178	Tiotropium as Add-On Therapy to ICS+LABA in Patients With Symptomatic Severe Asthma: Spirometric Assessment Over 24 Hours. <i>Chest</i> , 2013, 144, 91A.	0.8	3
179	Improvements in Lung Function With Tiotropium as Add-On Controller Therapy to ICS+LABA for Patients With Symptomatic Severe Asthma. <i>Chest</i> , 2013, 144, 88A.	0.8	2
180	Once-Daily Tiotropium Is Well Tolerated as Add-On to Standard Treatment for Patients With Symptomatic Asthma Despite Receiving Inhaled Corticosteroids and Long-Acting β_2 -Agonists. <i>Chest</i> , 2013, 144, 89A.	0.8	2

#	ARTICLE	IF	CITATIONS
181	Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2013, 8, 273.	2.3	12
182	Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. <i>European Respiratory Journal</i> , 2012, 40, 1098-1105.	6.7	53
183	An Association between Neutrophils and Immunoglobulin Free Light Chains in the Pathogenesis of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 817-824.	5.6	55
184	Bronchoscopic Lung Volume Reduction Coil Treatment of Patients With Severe Heterogeneous Emphysema. <i>Chest</i> , 2012, 142, 574-582.	0.8	170
185	Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy. <i>New England Journal of Medicine</i> , 2012, 367, 1198-1207.	27.0	578
186	Differential switching to IgG and IgA in active smoking COPD patients and healthy controls. <i>European Respiratory Journal</i> , 2012, 40, 313-321.	6.7	38
187	Excellent adherence and no contamination by physiotherapists involved in a randomized controlled trial on reactivation of COPD patients: a qualitative process evaluation study. <i>International Journal of COPD</i> , 2012, 7, 337.	2.3	0
188	Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1060-1068.	5.7	177
189	COPD exacerbations in general practice: variability in oral prednisolone courses. <i>BMC Family Practice</i> , 2012, 13, 3.	2.9	10
190	The validity and precision of the leicester cough questionnaire in COPD patients with chronic cough. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 4.	2.4	59
191	Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 308-314.	2.9	252
192	Community based physiotherapeutic exercise in COPD self-management: A randomised controlled trial. <i>Respiratory Medicine</i> , 2011, 105, 418-426.	2.9	92
193	Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. <i>Respiratory Medicine</i> , 2011, 105, 1853-1860.	2.9	50
194	The Effects Of Smoking On Corticosteroid-Induced Changes In Clinical And Inflammatory Variables In Asthma. , 2011, , .		0
195	Activation of WNT / β -Catenin Signaling in Pulmonary Fibroblasts by TGF- β 1 Is Increased in Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2011, 6, e25450.	2.5	128
196	Beta-Catenin Signaling Is Required For TGF-Beta1-Induced Ecm Production By Airway Smooth Muscle. , 2011, , .		0
197	Functional status measurement in COPD: a review of available methods and their feasibility in primary care. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2011, 20, 269-275.	2.3	79
198	Clinical predictors of exacerbation frequency in chronic obstructive pulmonary disease. <i>Clinical Respiratory Journal</i> , 2011, 5, 227-234.	1.6	16

#	ARTICLE	IF	CITATIONS
199	Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: A randomized controlled trial. <i>Respiratory Research</i> , 2011, 12, 112.	3.6	113
200	Respiratory symptoms in firefighters. <i>American Journal of Industrial Medicine</i> , 2011, 54, 350-355.	2.1	16
201	Serum pneumoproteins in firefighters. <i>Biomarkers</i> , 2011, 16, 364-371.	1.9	7
202	Beneficial Effects of Treatment With Anti-IgE Antibodies (Omalizumab) in a Patient With Severe Asthma and Negative Skin-Prick Test Results. <i>Chest</i> , 2011, 139, 190-193.	0.8	39
203	β -Catenin signaling is required for TGF- β ₁ -induced extracellular matrix production by airway smooth muscle cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2011, 301, L956-L965.	2.9	67
204	Antinuclear autoantibodies are more prevalent in COPD in association with low body mass index but not with smoking history. <i>Thorax</i> , 2011, 66, 101-107.	5.6	41
205	Relation Between Amoxicillin Concentration in Sputum of COPD Patients and Length of Hospitalization. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2011, 8, 66-70.	1.6	3
206	Volume-Targeted Versus Pressure-Targeted Noninvasive Ventilation in Patients With Chest-Wall Deformity: A Pilot Study. <i>Respiratory Care</i> , 2011, 56, 1522-1525.	1.6	7
207	Glycogen synthase kinase-3 regulates cigarette smoke extract- and IL-1 β -induced cytokine secretion by airway smooth muscle. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2011, 300, L910-L919.	2.9	19
208	Lung function, bronchial hyperresponsiveness, and atopy among firefighters. <i>Scandinavian Journal of Work, Environment and Health</i> , 2011, 37, 325-331.	3.4	19
209	The Smoke-induced Specific Immune Response Differs Between COPD Patients And Healthy Controls. , 2010, , .		0
210	Induction of autoantibodies against lung matrix proteins and smoke-induced inflammation in mice. <i>BMC Pulmonary Medicine</i> , 2010, 10, 64.	2.0	19
211	Two-year Nocturnal Noninvasive Ventilation Added To Rehabilitation In Hypercapnic COPD Patients. , 2010, , .		1
212	Uplifting results of tiotropium in moderate COPD (GOLD stage 2). <i>Evidence-Based Medicine</i> , 2010, 15, 44-45.	0.6	1
213	Health status in routine clinical practice: validity of the clinical COPD questionnaire at the individual patient level. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 135.	2.4	32
214	Chemical labeling and enrichment of nitrotyrosine-containing peptides. <i>Talanta</i> , 2010, 80, 1503-1512.	5.5	43
215	Asthma in Patients Climbing to High and Extreme Altitudes in the Tibetan Everest Region. <i>Journal of Asthma</i> , 2010, 47, 614-619.	1.7	18
216	Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 405-421.	1.8	20

#	ARTICLE	IF	CITATIONS
217	Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. <i>International Journal of COPD</i> , 2009, 4, 101.	2.3	74
218	An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 59-99.	5.6	1,591
219	(Cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in patients with COPD: the COPE II study. <i>Thorax</i> , 2009, 64, 956-962.	5.6	98
220	Definitions of Exacerbations. <i>Chest</i> , 2009, 136, 918-923.	0.8	52
221	Respiratory muscle activity and dyspnea during exercise in chronic obstructive pulmonary disease. <i>Respiratory Physiology and Neurobiology</i> , 2009, 167, 195-200.	1.6	31
222	Efficacy of a New Pulmonary Cyclosporine A Powder Formulation for Prevention of Transplant Rejection in Rats. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 486-492.	0.6	7
223	Increased levels of (class switched) memory B cells in peripheral blood of current smokers. <i>Respiratory Research</i> , 2009, 10, 108.	3.6	52
224	Protein Tyrosine Nitration: Selectivity, Physicochemical and Biological Consequences, Denitration, and Proteomics Methods for the Identification of Tyrosine-Nitrated Proteins. <i>Journal of Proteome Research</i> , 2009, 8, 3222-3238.	3.7	337
225	Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2009, 151, 517.	3.9	166
226	Development of a questionnaire for the assessment of bronchial hyperresponsiveness. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2009, 18, 287-293.	2.3	6
227	Respiratory effects in the aftermath of a major fire in a chemical waste depot. <i>Scandinavian Journal of Work, Environment and Health</i> , 2009, 35, 368-375.	3.4	11
228	Heme oxygenase-1 prevents smoke induced B-cell infiltrates: a role for regulatory T cells?. <i>Respiratory Research</i> , 2008, 9, 17.	3.6	25
229	Anti-Inflammatory Effects of Combined Budesonide/Formoterol in COPD Exacerbations. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2008, 5, 282-290.	1.6	33
230	Nitrogen Dioxide Exposure Attenuates Cigarette Smoke-Induced Cytokine Production in Mice. <i>Inhalation Toxicology</i> , 2008, 20, 183-189.	1.6	11
231	Poly(ethylene glycol)-Based Stable Isotope Labeling Reagents for the Quantitative Analysis of Low Molecular Weight Metabolites by LC-MS. <i>Analytical Chemistry</i> , 2008, 80, 9171-9180.	6.5	35
232	Nocturnal non-invasive ventilation in addition to rehabilitation in hypercapnic patients with COPD. <i>Thorax</i> , 2008, 63, 1052-1057.	5.6	128
233	Health-related quality of life in COPD patients with chronic respiratory failure. <i>European Respiratory Journal</i> , 2008, 32, 379-386.	6.7	46
234	GSK-3 β -catenin signaling axis in airway smooth muscle: role in mitogenic signaling. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008, 294, L1110-L1118.	2.9	39

#	ARTICLE	IF	CITATIONS
235	A new perspective on concepts of asthma severity and control. <i>European Respiratory Journal</i> , 2008, 32, 545-554.	6.7	372
236	Airways inflammation and treatment during acute exacerbations of COPD. <i>International Journal of COPD</i> , 2008, Volume 3, 217-229.	2.3	57
237	Copd. <i>Clinical Evidence</i> , 2008, 2008, .	0.2	0
238	Airway Remodeling in the Smoke Exposed Guinea Pig Model. <i>Inhalation Toxicology</i> , 2007, 19, 915-923.	1.6	54
239	Oral or IV Prednisolone in the Treatment of COPD Exacerbations. <i>Chest</i> , 2007, 132, 1741-1747.	0.8	119
240	Treatment of bronchiectasis in adults. <i>BMJ: British Medical Journal</i> , 2007, 335, 1089-1093.	2.3	39
241	Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study. <i>European Respiratory Journal</i> , 2007, 30, 1131-1137.	6.7	158
242	Safety of Sputum Induction During Exacerbations of COPD. <i>Chest</i> , 2007, 131, 432-438.	0.8	37
243	Effects of Short-Acting Bronchodilators Added to Maintenance Tiotropium Therapy. <i>Chest</i> , 2007, 132, 1493-1499.	0.8	22
244	Bidirectionality in the Relationship Between Asthma and Smoking in Adolescents: A Population-Based Cohort Study. <i>Journal of Adolescent Health</i> , 2007, 41, 444-454.	2.5	33
245	Selective Acylation of Primary Amines in Peptides and Proteins. <i>Journal of Proteome Research</i> , 2007, 6, 4770-4776.	3.7	57
246	Quality of life in smokers: focus on functional limitations rather than on lung function?. <i>British Journal of General Practice</i> , 2007, 57, 477-82.	1.4	5
247	Increased number of B-cells in bronchial biopsies in COPD. <i>European Respiratory Journal</i> , 2006, 27, 60-64.	6.7	88
248	Purification of decorin core protein from human lung tissue. <i>Journal of Chromatography A</i> , 2006, 1123, 151-159.	3.7	4
249	Cigarette Smoke-induced Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 751-758.	5.6	279
250	Female mice are more susceptible to the development of allergic airway inflammation than male mice. <i>Clinical and Experimental Allergy</i> , 2005, 35, 1496-1503.	2.9	215
251	Obtaining optimal control in mild asthma: theory and practice. <i>Family Practice</i> , 2005, 22, 305-310.	1.9	12
252	Discriminating asthma and COPD based on bronchodilator data: an improvement of the methods. <i>Physiological Measurement</i> , 2005, 26, 1115-1123.	2.1	14

#	ARTICLE	IF	CITATIONS
253	The GOLD Classification Has Not Advanced Understanding of COPD. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 212-213.	5.6	43
254	Short-Term Smoke Exposure Attenuates Ovalbumin-Induced Airway Inflammation in Allergic Mice. American Journal of Respiratory Cell and Molecular Biology, 2004, 30, 880-885.	2.9	88
255	Dissociation of Lung Function and Airway Inflammation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 499-504.	5.6	114
256	Provocation with adenosine 5'-monophosphate, but not methacholine, induces sputum eosinophilia. Clinical and Experimental Allergy, 2004, 34, 71-76.	2.9	44
257	Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clinical and Experimental Allergy, 2004, 34, 632-638.	2.9	490
258	The role of endogenous and exogenous AMP in asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2004, 114, 737-746.	2.9	46
259	Cognitive performance in patients with COPD. Respiratory Medicine, 2004, 98, 351-356.	2.9	130
260	Perimenstrual asthma: A syndrome without known cause or cure. Journal of Allergy and Clinical Immunology, 2003, 112, 271-282.	2.9	100
261	Effect of SCH55700, a Humanized Anti-Human Interleukin-5 Antibody, in Severe Persistent Asthma. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 1655-1659.	5.6	473
262	Phosphodiesterase 4 Inhibitors. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 914-915.	5.6	5
263	Sputum Induction in Research. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1253-1253.	5.6	1
264	Initial Improvements in Lung Function and Bronchial Hyperresponsiveness Are Maintained During 5 Years of Treatment With Inhaled Beclomethasone Dipropionate and Terbutaline. Chest, 2002, 121, 151-157.	0.8	128
265	A Systematic Review of the Effects of Bronchodilators on Exercise Capacity in Patients With COPD. Chest, 2002, 121, 597-608.	0.8	77
266	Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clinical and Experimental Allergy, 2002, 32, 1096-1103.	2.9	98
267	Recent advances: Respiratory medicine. BMJ: British Medical Journal, 2001, 323, 1349-1353.	2.3	14
268	Corticosteroid-induced Improvement in the PC ₂₀ of Adenosine Monophosphate Is More Closely Associated with Reduction in Airway Inflammation than Improvement in the PC ₂₀ of Methacholine. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 1127-1132.	5.6	160
269	PC ₂₀ Adenosine 5' -Monophosphate Is More Closely Associated with Airway Inflammation in Asthma Than PC ₂₀ Methacholine. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 1546-1550.	5.6	239
270	Effects of inhaled fluticasone and oral prednisolone on clinical and inflammatory parameters in patients with asthma. Thorax, 1999, 54, 894-899.	5.6	96

#	ARTICLE	IF	CITATIONS
271	Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. <i>Thorax</i> , 1999, 54, 7-14.	5.6	136
272	The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs. <i>Journal of Allergy and Clinical Immunology</i> , 1998, 101, 342-348.	2.9	54
273	Decline of FEV1 by age and smoking status: facts, figures, and fallacies. <i>Thorax</i> , 1997, 52, 820-827.	5.6	231
274	Comparison of guidelines and self-management plans in asthma. <i>European Respiratory Journal</i> , 1997, 10, 1163-1172.	6.7	45
275	Corticosteroids and IgE. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 138.	2.9	4
276	Combination of Inhaled Corticosteroids and β_2 -Agonists in Asthma. <i>BioDrugs</i> , 1996, 6, 489-505.	0.7	5
277	Is Delayed Introduction of Inhaled Corticosteroids Harmful in Patients With Obstructive Airways Disease (Asthma and COPD)? <i>Chest</i> , 1996, 110, 35-41.	0.8	88
278	Risk Factors for Accelerated Decline Among Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1996, 154, S266-S272.	5.6	32
279	Inhaled β_2 -Agonists in the Treatment of Asthma. <i>New England Journal of Medicine</i> , 1996, 335, 886-888.	27.0	17
280	Costs and Effects of Inhaled Corticosteroids and Bronchodilators in Asthma and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995, 151, 975-982.	5.6	0
281	Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group. <i>Thorax</i> , 1994, 49, 1109-1115.	5.6	78
282	Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. <i>Thorax</i> , 1994, 49, 652-656.	5.6	74
283	Interpretation of skin tests to house dust mite and relationship to other allergy parameters in patients with asthma and chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 1993, 91, 560-570.	2.9	40
284	Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. <i>Thorax</i> , 1993, 48, 722-729.	5.6	49
285	A Comparison of Bronchodilator Therapy with or without Inhaled Corticosteroid Therapy for Obstructive Airways Disease. <i>New England Journal of Medicine</i> , 1992, 327, 1413-1419.	27.0	343
286	Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. <i>Thorax</i> , 1992, 47, 429-436.	5.6	180
287	Relationship of Airway Hyperresponsiveness to Respiratory Symptoms and Diurnal Peak Flow Variation in Patients with Obstructive Lung Disease. <i>The American Review of Respiratory Disease</i> , 1991, 143, 916-921.	2.9	88